

DAFTAR PUSTAKA

- Alho O.P., Hannula K., Luukkala A., Teppo H., Koivunen P. and Kantola S. 2007. Differential prognostic impact of comorbidity in head and neck cancer. *Head Neck*, 29, 913-8.
- Andisheh-Tadbir A., Ashrafi M.J., Jafari-Ashkavandi Z., Paknahad M. and Taheri F. 2008. Head and neck squamous cell carcinoma in Southern Iran. *Iran Red Crescent Med J*, 10, 309-13.
- Andrews GA., Xi S., Pomerantz RG. Lin CJ, Gooding WE. and Wentzel A.L. *et al.* 2004. Mutation of P53 in Head and Neck Squamous cell carcinoma correlates with Bcl-2 Expression and increased susceptibility to Cisplatin – induced apoptosis. *Head Neck* 26: 870–877.
- Antognoni P., Corvo R., Zerini D., and Orecchia R. 2005. Altered fractionation radiotherapy in head and neck cancer: clinical issues and pitfalls of "evidence-based medicine". *Tumori*, 91, 30-9.
- Argiris A., Brockstein B.E., Haraf D.J., Stenson K.M., Mittal B.B. *et al.* 2004. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. *Clin Cancer Res*, 10, 1956-62.
- Barber B.R., Biron V.L., Klimowicz A.C., Puttagunta L. and David WJ. 2013. Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma. *Journal of Otolaryngology - Head and Neck Surgery*, 42:53.
- Barnes L., Eveson J.W., Reichart P. and Sidransky D. 2005. Head and Neck Tumours Pathology & Genetics World Health Organization Classification of Tumours. *International Agency for Research on Cancer (IARC)*.
- Baumann M. and Krause M. (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. *Radiother Oncol*, 72, 257-66.
- Bergers G., Brekken R., Mc Mahon G., Vu T.H., Itoh T. and Tamaki K. *et al.* 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nat Cell Biol.* ;2(10):737-44.

- Bhatt A.N., Mathur R., Farooque R., Verma A. and Dwarakanath B.S.
2010. Cancer biomarkers - Current perspectives. *Indian J Med Res* 132, , pp 129-149
- Bhattacharyya N. 2003. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. *Laryngoscope*, 113, 368-72.
- Blons H. and Puig P.L. 2003. TP53 and Head and Neck Neoplasms. *Hum Mutat* 21:252–257.
- Blot W.J., McLaughlin J.K., Winn D.M., Austin D.F., Greenberg R.S. and Preston-Martin S. *et al* (1988). Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res*, 48, 3282-7.
- Bonner J.A., Harari P.M., Giralt J., Cohen R.B., Jones C.U. and Sur R.K. *et al*. 2010. "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival." *Lancet Oncol* 11(1): 21-28.
- Boslooper K., Lam A.K.Y., Gao J., Weinstein S. and Johnson N. 2007. The Clinicopathological Roles of Alpha B-Crystallin and p53 expression in patients with Head and Neck Squamous cell carcinoma . Paper, was presented in the First World Congress of the International Academy of Oral Pathology, Amsterdam.
- Bourdon J.C. 2007. p53 and its isoforms in cancer. *British Journal of Cancer* 97, 277 – 282.
- Bourhis J., Calais G., Lapeyre M., Tortochaux J., Alfonsi M. and Sire C. *et al*. 2004. Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). *Semin Oncol*, 31, 822-6.
- Bourhis J., Overgaard J., Audry H., Ang K,K., Saunders M. and Bernier J, *et al*. 2006. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet*, 368, 843-54.
- Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H. and Roa R.A. *et al*. 1993. The incidence of p53 mutations increases with progression of head and neck cancer. *Cancer Res* 53:4477-4480.

- Boyle, P. and Levin, B. World Cancer Report 2008. Lyon: International Agency for Research on Cancer; Available from: <http://www.iarc.fr/en/publications/pdfs->
- Braakhuis B.J.M., Senft A., de Bree R., de Vries J, Ylstra B. and Cloos J. 2006. Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. *J Clin Pathol* ;59:1254–1260.
- Bradford C.R., Zhu S., Ogawa H., Ogawa T., Ubell M. and Narayan A. 2003. P53 Mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. *Head Neck* 25: 654–661, 2003.
- Brandt-Rauf P.W. and Pincus M.R. 1998. Molecular markers of carcinogenesis. *Pharmacol Ther.* 77:135-148.
- Brizel D.M. and Esclamado R. 2006. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. *J Clin Oncol*, 24, 2612-7.
- Bruggers C.S., Tai K.F., Murdock T, Todd, Sivak L. and Le K. *et al.* 1998. Expression of the c-Myc protein in childhood medulloblastoma. *J Pediatr Hematol Oncol.* ;20:18-25.
- Cabanillas R., Rodrigo J.P., Astudillo A., Dominguez F., Suarez C. and Chiara. 2007. P53 Expression in Squamous Cell Carcinomas of the Supraglottic Larynx and its Lymph Node Metastases. *Cancer* ;109:1791–8.
- Carvalho A.L., Nishimoto I.N., Califano J.A. and Kowalski L.P. 2005. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. *Int J Cancer*, 114, 806-16.
- Cellai E., Frata P., Magrini S.M., Paiar F., Barca R. and Fondelli S. *et al.* . 2005. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. *Int J Radiat Oncol Biol Phys*, 63: 1378-1386.
- Chambers M.S., Day T.A., Lewin J.S., Lydiatt W.M., Murphy B. and Peterson D.E. *et al.* 2005. A Team Approach to Treating Head and Neck Cancer www.cancer.org.

- Chen A.M., Chen L.M., Vaughan A., Sreeraman R., Farwell D.G. and Luu Q. *et al.* 2011. Tobacco Smoking During Radiation Therapy for Head-and-Neck Cancer Is Associated With Unfavorable Outcome. *Int J Radiat Oncol Biol Phys.* Feb 1;79(2):414-9.
- Chrzan P., Skokowski J., Jarmolinski A. and Pawelczyk T. 2001. Amplification of *c-myc* gene and overexpression of c-Myc protein in breast cancer and adjacent nonneoplastic tissue. *Clin Biochem.* 34:557-562.
- Chung C.H. and Gillison M.L. 2009. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. *Clin Cancer Res* 15(22): 6758–6762.
- Clark J., Li W., Smith G., Shannon K., Clifford A. and McNeil E. *et al.* 2005. Outcome of treatment for advanced cervical metastatic squamous cell carcinoma. *Head Neck*, 27, 87-94.
- Cohan D.M., Popat S., Kaplan S.E., Rigual N., Loree T. and Hicks WL, Jr. 2009. Oropharyngeal cancer: current understanding and management. *Curr Opin Otolaryngol Head Neck Surg*, 17, 88-94.
- Cortesina G. and Martone T. 2006. Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. *Acta Otorhinolaryngol Ital.* ;26(6):317-25.
- Corvo R. 2007. Evidence-based radiation oncology in head and neck squamous cell carcinoma. *Radiother Oncol*, 85, 156-70.
- Costa A., Licitra L., Veneroni S., Daidone M.G., Grandi C. and Cavina R. *et al.* 1998. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. *Int J Cancer*, 79: 619-623.
- Crowe D.L. and Sinha U.K. 2006. p53 Apoptotic Response to DNA Damage Dependent Bcl-2 but not Bax in Head and Neck Squamous Cell Carcinoma Lines. *Head Neck* 28:15–23.
- Daele J.J., Poorten V.V., Rombaux P. and Hamoir M. 2005. Cancer of the nasal vestibule, nasal cavity and paranasal sinuses B-ENT, 1, *Suppl.* 1, 87-96.

- Dahlstrom K.R., Little J.A., Zafereo M.E., Lung M., Wei Q. and Sturgis E.M. 2008. Squamous cell carcinoma of the head and neck in never smoker–never drinkers: a descriptive epidemiologic study. *Head Neck*, 30, 75-84.
- Dasgupta S., Dash R., Das S.K., Sarkar D. and Fisher P.B. 2012. Emerging Strategies for the Early Detection and Prevention of Head and Neck Squamous Cell Cancer. *J Cell Physiol*. 227(2): 467–473.
- Delia D., Ajello A. and Soligo D. 1992. *Bcl-2* proto-oncogene expression in normal and neoplastic human myeloid cells. *Blood*. 1992;79:1291-1298.
- De Paula A.M., Souza L.R., Farias L.C., Corrêa G.T., Fraga C.A. and Eleutério N.B. *et al.* 2009. Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. *Oral Oncol* ;45(9):777-82.
- D'Souza G., Zhang H.H., D'Souza W.D., Meyer R.R. and Gillison M.L. 2010. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. *Oral Oncol* 46(2): 100–104.
- Diaz E.M., Holsinger F.C., Zuniga E.R., Roberts D.B. and Sorensen D.M. 2003. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. *Head Neck*;25:267–73.
- Dietz A., Ramroth H., Urban T., Ahrens W. and Becher H. 2004. Exposure to cement dust, related occupational groups and laryngeal cancer risk: results of a population based case-control study. *Int J Cancer* 108(6): 907–911.
- Dinshaw K.A., Sharma V., Agarwal J.P., Ghosh S. and Havaladar R. 2000. Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications. *Int J Radiat Oncol Biol Phys*, 48: 723-735.
- Doni L., Perin A. and Manzione L. 2010. The impact of anemia on quality of life and hospitalisation in elderly cancer patients undergoing chemotherapy. *Crit Rev Oncol Hematol*.
- Edge S.B.B., Compton, Fritz C.C., Greene F.L and Trotti, A. editor. 2010. The AJCC Cancer Staging. *Manual and Handbook*. The Seventh Edition Springer, Chicago.

- Facchini L.M. and Penn L.Z. 1998. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. *FASEB J.* 12:633-651.
- Faye-Lund H. and Abdelnoor M. 1996. Prognostic factors of survival in a cohort of head and neck cancer patients in Oslo. *Eur J Cancer B Oral Oncol*, 32B, 83-90.
- Ferlay J., Shin H.R., Bray F., Forman D., Mathers C. and Parkin D.M. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127(12): 2893–2917.
- Forastiere A.A., Goepfert H. and Maor M. 2003. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med*, 349, 2091-8.
- Fouret P., Temam S., F Charlotte and Guily J.L. 2002. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. *British Journal of Cancer* : 87, 1390 – 1395.
- Freier K., Bosch F.X., Flechtenmacher C., Devens F., Benner A. and Lichter P. *et al.* 2003. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. *Anticancer Res.* ;23(5A):3971-7.
- Furness S., Glenny A.M., Worthington H.V., Pavitt S., Oliver R. and Clarkson J.E. 2010. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. *Cochrane Database Syst Rev* 4:CD006386.
- Gallo O., Chiarelli I., Boddi V., Bocciolini C., Bruschini L. and Porfirio B. 1999. Cumulative prognostic value of p53 mutation and bcl-2 protein expression in head and neck cancer treated by radiotherapy. *Int. J. Cancer (Pred. Oncol.)* 84:573–579.
- Gamel J.W. and Jones A.S. 1993. Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histological type, and node status. *Br J Cancer.* 67:1071-1075.
- Gawecki W., Szyfter K. and Szyfter W. 2007. Clinical and histopathological analysis of squamous cell carcinoma of the head and neck in young adults. *Otolaryngol Pol*, 61, 11-6.

- Gibson, M.K. and Forastiere A.A. 2004. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. *Curr Opin Oncol* 16:220-224.
- Grabenbauer G.G., Muhlriedel C.H and Rodel.2000. Squamous cell carcinoma of the oropharynx: ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. *Int J Radiat Oncol Biol Phys* ;48:1041–1050.
- Grange F., Petrella T., Barry M.B., Joly P., D'Incan M. and Delaunay M. 2004. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. *Blood* :103:3662-3668.
- Greene F.L. 2007. A cancer staging perspective: the value of anatomical staging. *J Surg Oncol*, 95, 6-7.
- Groome P.A., O'Sullivan B., Irish J.C., Rothwell D.M., Math K.S. and Bissett R.J. *et al.* 2001. Glottic cancer in Ontario, Canada and the SEER areas of the United States. Do different management philosophies produce different outcome profiles? *J Clin Epidemiol*, 54, 301-15.
- Gurlek U., Abakay C.D., Ozkan L., Saraydaroglu O., Kurt M. and Cetintas S.K. 2013. The evaluation of *bcl-2* expression as a prognostic marker in early stage laryngeal cancer. *Tumori* ;99(6):682-688.
- Haddad RI. and Shin DM. 2008. Recent Advances in Head and Neck Cancer. *N Engl J Med* ;359:1143-54.
- Hanahan D. and Weinberg, R.A. 2000. The Hallmarks of Cancer. *Cell*, 100: 57-70.
- Harrison L.B., Chadha M., Hill R.J., Hu K. and Shasha D. 2002. Impact of tumor hypoxia and anemia on radiation therapy outcomes. *Oncologist*, 7, 492-508.
- Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C. and Curado M.P. *et al.* 2007. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *J Natl Cancer Inst* ;99(10):777-89.

- Hayry V., Ma`kinen L.K., Atula T., Sariola H., Ma`kitie A. and Leivo I. 2010. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. *British Journal of Cancer* 102, 892 – 897.
- Higgins K.M., Shah M.D., Ogaick M.J. and Enepekides D. 2009. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. *J Otolaryngol Head Neck Surg*, 38, 603-12.
- Hitt R., López-Pousa A., Martínez-Trufero J., Escrig V., Carles J. and Rizo A. *et al.* 2005. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol*, 23, 8636-45.
- Homann N., Nees M. and Conradt C. 2009. Over expression of p53 in Tumor-distant Epithelia of Head and Neck Cancer Patients Is Associated with an Increased Incidence of Second Primary Carcinoma *Clin Cancer Res*;7:290-296.
- Horner M.R.L. and Krapcho, M. 2009. SEER Cancer Statistics Review, 1975-2006.
- Hu K. and Harrison L.B. 2005. Impact of anemia in patients with head and neck cancer treated with radiation therapy. *Curr Treat Options Oncol*, 6, 31-45.
- Ingle C.J., Yip K., Caskie V., Dyson C., Ford A. and Scrase C.D. 2010. Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score - report from a single U.K. institution. *Head & Neck Oncology* , 2:28.
- Ismail H.M., Baradie M.E., Mpneer M., Khorsid O. and Touny A. 2007. Clinico-Pathological and Prognostic Significance of p53,Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray. *Journal of the Egyptian Nat. Cancer Inst.*, Vol. 19, No. 1, March: 3-14.

- Iyer S.G., Pradhan S.A., Pai P.S. and Patil S. 2004. Surgical treatment outcomes of localized squamous carcinoma of buccal mucosa. *Head Neck* ;26:897–902.
- Jung A.C., Briolat J., Millon R., de Reynies A., Rickman D. and Thomas E. *et al* .2010. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. *Int J Cancer* 126(8): 1882–1894.
- Kapranos N., Stathopoulos G.P., Manolopoulos L., Kokka E., Papadimitriou C. and Bibas A. 2001.p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. *Anticancer Res.* Jan-Feb;21(1B):521-8.
- Karamouzis M.V., Argiris A. and Grandis J.R. 2007. Clinical Applications of Gene Therapy in Head and Neck Cancer. Volume: 7 ISSUE: 6 Page: 446 – 457.
- Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T. and Nonaka S. *et al* . 2004. Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and PrognosisClinical. *Cancer Research* Vol. 10, 634–640, January 15.
- Kaur H. and Gupta S. 2013. An Analysis of the Expression of Bcl-2, Podoplanin and Lymph Angiogenesis in Benign and Malignant Salivary Gland Tumours. *J Clin Exp Pathol* 3:3.
- Kazkayasi M., Hücümeno lu S., Siriner G.I. and Hücümeno lu M. 2001. Over-expression of p53 and c-erbB-2 oncoproteins in laryngeal carcinoma.*Eur Arch Otorhinolaryngol.* Sep;258(7):329-35.
- Kim E.Y., Eisele D.W., Goldberg A.N., Maselli J. and Kezirian E.J. 2011. Neck dissections in the United States from 2000 to 2006: volume, indications, and regionalization. *Head Neck.* ;33(6):768-73.
- Kim M.M. and Califano J.A. 2004. Molecular Pathology of Head and Neck Cancer. *Int. J. Cancer:* 112, 545–553.
- Klatka J. 2001. Prognostic value of the expression of p53 and bcl-2 in patients with laryngeal carcinoma. *European Archives of Oto-Rhino-Laryngology* December. Volume 258, Issue 10, pp 537-541.

- Koch W.M., Brennan J.A., Zahurak M., Goodman S.N., Westra W.H. and Schwab D. *et al.* 1996. p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell Carcinoma. *J Natl Cancer Inst* ;88:1580-6.
- Krstevska V., Stojkovski I. and Lukarski D. 2010. Concurrent radiochemotherapy in advanced hypopharyngeal cancer. *Radiation Oncology* 5:39.
- Kumar V., Abbas A.K. and Fausto N., 2005. *Robbins and Cotran Pathologic Basis of Disease*. 7th ed. Philadelphia, Elsevier.
- Kumar B., Cordell K.G., D'Silva N., Prince M.E., Adams M.E. and Fisher SG. 2008. Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer. *Arch Otolaryngol Head Neck Surg*. 134(4):363-369.
- Lajer C.B and von Buchwald C. 2010. The role of human papillomavirus in head and neck cancer. *APMIS* 118(6-7): 510-519.
- Lane D.P. 1992. "Cancer. p53, guardian of the genome." *Nature* 358(6381):15-16.
- Laskar S.G., Agarwal J.P., Srinivas C. and Dinshaw K.A. 2006. Radiotherapeutic management of locally advanced head and neck cancer. *Expert Rev Anticancer Ther*, 6, 405-17.
- La Vecchia C., Tavani A., Franceschi S., Levi F., Corrao G. and Negri E. 1997. Epidemiology and prevention of oral cancer. *Oral Oncol*, 33, 302-12.
- Lawrence T.S., Blackstock A.W. and Mc Ginn C. 2003. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. *Semin Radiat Oncol*, 13, 13-21.
- Leemans C.R., Braakhuis B.J. and Brakenhoff R.H. 2011. The molecular biology of head and neck cancer. *Nat Rev Cancer* 11(1): 9-22.
- Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L. and Sahnoud T. 1996. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. *J Natl Cancer Inst*, 88, 890-9.

- Lehr H.A., Loss C.M., Teeling P. and Gown A.M. 1999. Complete Chromogen Separation and Analysis in Double Immunohistochemical Stains Using Photoshop-based Image Analysis. *J Histochem Cytochem* 47: 119. <http://jhc.sagepub.com>
- Liao C.T., Wang H.M., Ng SH., Yen T.C., Lee L.Y. and Hsueh C. *et al.* 2006. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. *Oral Oncol* ;42:800–9.
- Licitra L., Bossi P. and Locati L.D. 2006. A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new? *Curr Opin Oncol* 18:253-257.
- Lin D.T., Cohen S.M., Coppit G.L. and Burkey BB. 2005. Squamous cell carcinoma of the oropharynx and hypopharynx. *Otolaryngol Clin North Am*, 38, 59-74, viii.
- Liu S., Lou W., Sang J., Zhao M. and Meng Z. 2007. Expression of P53 and Bcl-2 in laryngeal squamous cell carcinoma. *Life Science Journal*, Vol 4, No 1.
- Liu Z., Li L., Yang Z., Luo W., Li X. and Yang H. *et al.* 2010. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. *BMC Cancer* , 10:270.
- Llewellyn C.D., Linklater K., Bell J., Johnson N.W. and Warnakulasuriya S. 2001. An analysis of risk factors for oral cancer in young people: a case–control study. *Oral Oncol* ;40(3):304–313.
- Lo M.L., Falaschini S., Farina A., Rubini C., Pezzetti F. and Campisi G. *et al.* 2005. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. *Oncol Res.*;15(5):249-55.
- Lothaire P., Azambuja E., Dequanter D., Lalami Y., Sotiriou C. and Andry G. *et al* Molecular Markers of Head and Neck Squamous Cell Carcinoma : Promising Sign in Need of Prospective Evaluation. *Head Neck* 28: 256– 269, 2006.
- Lusinchi A., Bourhis J., Wibault P., Le Ridant A.M. and Eschwege F. 1990. Radiation therapy for head and neck cancers in the elderly. *Int J Radiat Oncol Biol Phys.*18(4): 819–23.

- McGregor G.I., Davis N. and Robins R.E. 1983. Squamous cell carcinoma of the tongue and lower oral cavity in patients under 40 years of age. *Am J Surg*, **146**, 88-92.
- McLaughlin J.K., Gridley G., Block G., Winn D.M., Preston-Martin S. and Schoenberg J.B. *et al.* 1988. Dietary factors in oral and pharyngeal cancer. *J Natl Cancer Inst*, **80**, 1237-43.
- McNeil B.J., Weichselbaum R. and Pauker S.G. 1981. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. *N Engl J Med*, **305**, 982-7.
- Marron M., Boffetta P., Zhang Z.F., Zaridze D., Wunsch-Filho V. and Winn D.M. *et al.* 2010. Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. *Int J Epidemiol*, **39**, 182-96.
- Marur S. and Forastiere A.A. 2008. Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment. *Mayo Clin Proc.*;83(4):489-501
- Mehanna H., Paleri V., West C.M., and Nutting C. 2011. Head and neck cancer part 1: epidemiology, presentation, and preservation. *Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery* **36**, 65-68.
- Mendenhall W.M., Werning J.W., Hinerman R.W., Amdur R.J and Villaret D.B. 2004. Management of T1-T2 glottic carcinomas. *Cancer*, **100**, 1786-92.
- Moreno R.A.F., Kemkes A.C., Xiu J., Blevins R., Esmay P., and Battaglia L. *et al.* 2012. Differences in biomarker expression in HNSCC according to p53 status. *J Clin Oncol* **30**.
- Muller P.A.J., Vousden K.H. and Norman J.C. 2011. p53 and its mutants in tumor cell migration and invasion. *J. Cell Biol.* Vol. 192 No. 2 209–218,
- Muscat J.E. and Wynder E.L. 1992. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. *Cancer* **69**(9): 2244–2251.

- Muzio LL., Farina A, Rubini C., Pezzetti F., Stabellini G. and Laino G. 2005. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. *Cancer*, Volume 225, Issue 1, Pages 27–33.
- Myers E.N.S., Myers J.N. and Hanna E.Y.N. editor. 2003. *Cancer of the Head and Neck*. Saunders, Philadelphia.
- Nishioka H., Hiasa Y., Hayashi I., Kitahori Y., Konishi N. and Sugimura M.1993. Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. *Oncology* ;50:426–429.
- Nylander K., Dabelsteen E. and Hall PA. 2000. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. *J Oral Pathol Med* ;29:413–425.
- OHSU Cancer Committee .2009 .Annual Report. OHSU KNIGHT CANCER INSTITUTE.
- O'Hara J. and Mac Kenzie K. 2011. Surgical versus non-surgical management of early stage oropharyngeal squamous cell carcinoma. *Eur Arch Otorhinolaryngol* 268(3):437-42.
- O'Regan E.M., Timon C., Sheils O. *et al* .2006. Squamous cell carcinoma of the head and neck in young Irish adults. *Br J Oral Maxillofac Surg*, 44, 203-6.
- Osborne R.F. and Brown J.J. 2004. Carcinoma of the oral pharynx: an analysis of subsite treatment heterogeneity. *Surg Oncol Clin N Am*, 13, 71-80.
- Ostroff J.S., Jacobsen P.B. and Moadel A.B. 1995. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. *Cancer*, 75, 569-76.
- Papakosta V., Vairaktarisi E., Vylliotis A. Derka S., Nkenkes E. and Vassilioui S. *et al* . 2006. The Co-expression of c-myc and p53 Increases and Reaches a Plateau Early in Oral Oncogenesis. *Anticancer Research*. 26: 2957-2962.
- Patel S.C., Carpenter W.R., Tyree S., Couch M.E., Weissler M. and Hackman T. *et al* . 2011. Increasing incidence of oral tongue

squamous cell carcinoma in young white women, age 18 to 44 years. *J Clin Oncol*, 10, 1488-94.

Patel B.P., Shah S.V., Shukla S.N., Shah P.M. and Patel P.S. 2007. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. *Head Neck*, 29(6):564-572.

Pena J.C., Thompson CB., Recant W., Vokes E.E. and Rudin C.M. 1999. Bcl-xL and Bcl-2 Expression in Squamous Cell Carcinoma of the Head and Neck. *Cancer* ;85:164-70.

Pera E., Moreno A. and Galindo L. 1986. Prognostic factors in laryngeal carcinoma. *Cancer*, 58: 928-934.

Peters L.J. and Withers H.R. 1997. Applying radiobiological principles to combined modality treatment of head and neck cancer--the time factor. *Int J Radiat Oncol Biol Phys*, 39, 831-6.

Pfister D.G., Laurie S.A and Weinstein G.S. 2006 American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. *J Clin Oncol*, 24, 3693-704.

Pignon J.P., Maitre A., Maillard E. and Bourhis J. 2009. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol*, 92, 4-14.

Poorten V.V., Hart A. and Vauterin T. 2009. Prognostic index for patients with parotid carcinoma: international external validation in a Belgian-German database. *Cancer*, 115, 540-50.

Posner M.R., Hershock D.M. and Blajman C.R. 2007. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med*, 357, 1705-15.

Psyrrri A., Licitra L., Lacombe D., Schuurin E., Budach W. and Ozsahin M. *et al.* 2010. Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. *Ann Oncol* 21(10): 1952-1960.

- Rastogi R.P., Richa and Sinha R.P. 2013. An Analysis of the Expression of Bcl-2, Podoplanin and Lymph Angiogenesis in Benign and Malignant Salivary Gland Tumours. *J Clin Exp Pathol.* 3:3.
- Reed J.C. Bcl-2 and the regulation of programmed cell death. *J Cell Biol.* 1994 Jan;124(1-2):1-6.
- Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B. and Kilian U. *et al.* 2001. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. *Clin Cancer Res.* ;7(10):2984-97.
- Riethdorf S., Friedrich R.E. and Ostwald C. 1997. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival—a long term follow-up study. *J Oral Pathol Med* ;26:315–321.
- Ridge J.A., Glisson B.S., Horwitz E.M. and Meyers M.O. Head and neck tumors : . Cancer management : a multidisciplinary approach. Chapter 4 :39-86.
- Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller B.A. and Feuer E.J. *et al.* SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/
- Riskesdas 2013. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI.
- Robbins and Cotran. 2005. *Pathologic Basis of Disease.* 7th ed. WB Saunders Co. Philadelphia, 309-13.
- Robinson K.L. and Macfarlane G.J. 2003. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? *Oral Oncol*, 39, 31-6.
- Rodrigo, Ferlito A., Suarez C., Shaha AR., Silver CE. and Devaney KO. 2005. New Molecular Diagnostik Methods in Head and Neck Cancer. *Head Neck* 27: 995– 1003.
- Rosenthal E.L. and Matrisian L.M. 2006. Matrix Metalloproteases in Head and Neck Cancer. *Head Neck.* 28: 639–648.

- Ruokolainen H., Pääkkö P. and Turpeenniemi H.T. 2004. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. *Clin Cancer Res.* 10(9):3110-6.
- Ruokolainen H. 2005. The prognostic role of Matrix Metalloproteinase-2 and 9 (MMP-2, MMP-9) and their tissue inhibitor -1 and -2 (TIMP-1, TIMP-2) in Head and Neck Squamous Cell Carcinoma. Academic. *Dissertation.* OULU UNIVERSITY PRESS.
- Sanabria A., Carvalho A.L., Vartanian J.G., Magrin J., Ikeda M.K. and Kowalski L.P. 2007. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. *Ann Surg Oncol*, 14, 1449-57.
- Sarini J., Fournier C., Lefebvre J.L., Bonafos G., Van J.T. and Coche-Dequeant B. 2001. Head and neck squamous cell carcinoma in elderly patients: a long term retrospective review of 273 cases. *Arch Otolaryngol Head Neck Surg.* ;127:1089-92.
- Schaaij-Visser T.B., Brakenhoff R.H., Leemans C.R., Heck A.J. and Slijper M. 2010. Protein biomarker discovery for head and neck cancer. *J Proteomics* 73(10): 1790-1803.
- Schantz S.P. and Yu G.P. 2002. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. *Arch Otolaryngol Head Neck Surg*, 128, 268-74.
- Shi Y., Glynn J.M. and Guilbert L.J. 1992. Role for c-Myc in activation-induced apoptotic cell death in T cell hybridomas. *Science.* 257:212-214.
- SIGN. 2006. Diagnosis and management of head and neck cancer: A national clinical guideline. Scottish Intercollegiate Guidelines Network.
- Simsek, G., Han Ü., Unal B., Koybasioglu F.F., Akin . and Dagli M. 2013. Expression of cyclin D1, p27, p21, bcl-2, and p53 in laryngeal squamous cell carcinoma and an investigation of the correlation with conventional prognostic factors. *Turk J Med Sci* 43: 27-32.
- Sittel C., Ruiz S., Volling P., Kvasnicka H.M., Jungehu" Ising M. and Eckel H.E. 1999. Prognostic significance of Ki-67 (MIB1), PCNA and

p53 in cancer of the oropharynx and oral cavity. *Oral Oncol* ;35:583–589.

Skladowski K., Tarnawski R., Maciejewski B., Wygoda A. and Slosarek K. 1999. Clinical radiobiology of glottic T1 squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*, 43, 101-6.

Snow A.N. and Laudadio J. 2010. Human papillomavirus detection in head and neck squamous cell carcinomas. *Adv Anat Pathol* 17(6): 394–403.

Sturgis E.M. and Cinciripini P.M. 2007. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? *Cancer*, 110, 1429-35.

Su H.H., Chu S.T, Hou Y.Y., Cheng K.P. and Chen C.J. 2006. Spindle cell carcinoma of the oral cavity and oropharynx: factors affecting outcome. *J Chin Med Assoc* ;69:478–83.

Sudiana I.K. 2008. Patobiologi Molekuler Kanker, Salemba medika, Jakarta, 53-9.

Takes R.P., Rinaldo A., Silver C.E., Piccirillo J.F., Haigentz M. and Suárez C. *et al.* 2010. Future of the TNM classification and staging system in head and neck cancer. *Head Neck*. 32(12):1693-711.

Temam S., Flahault A., Pe´rie S., Monceaux G., Coulet F. and Callard P. *et al.* 2000. p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck. *J Clin Oncol* 18:385-394.

Thomas G.R., Nadiminti H. and Regalado J. 2005. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. *Int. J. Exp. Path.* 86, 347–363.

Thompson B.E. 1998. The many roles of Myc in apoptosis. *Annu Rev Physiol.* ;60:575-600.

Toner M. and O'Regan E.M. 2009. Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 1. *Head Neck Pathol* 3(3): 246–248.

- Trivedi T.I., Tankshali R.A., Goswami J.V., Shukla S.N., Shah P.M. and Shah N.G. 2001. Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma. *Neoplasma* 58-3.
- Unal O.F., Ayhan A. and Hosal A.S. 1999. Prognostic value of p53 expression and histopathologic parameters in squamous cell carcinoma of oral tongue. *J Laryngol Otol* ;113:446–450.
- Vahakangas K. 2003. TP53 Mutations in Workers Exposed to Occupational Carcinogens. *Hum Mutat* 21:240–251.
- Vermorken J.B., Mesia R., Rivera F., Remenar E., Kaweckki A. and Rottey S.
et al. 2008. "Platinum-based chemotherapy plus cetuximab in head and neck cancer." *N Engl J Med* 359(11): 1116-1127.
- Vicente J.C., Gutierrez L.M.J., Zapatero A.H., Forcelledo M.F.F., Vallejo G.H. and Arranz J.S.L. 2004. Prognostic Significance of P53 Expression in Oral Squamous Cell Carcinoma without neck node metastases. *Head Neck* 26: 22– 30.
- Vokes E.E., Weichselbaum R.R., Lippman S.M. and Hong W.K. 1993. Head and Neck cancer. *N Engl J Med*, **328**, 184-94.
- Waddell W.J. and Levy P.S. 2000. "Interaction between tobacco and alcohol consumption and the risk of cancers of the upper aero-digestive tract in Brazil". *Am J Epidemiol.* 15;152(2):193–4
- Waitzberg A.F, Nonogaki S., Nishimoto I.N., Kowalski L.P., Miguel R.E. and Brentani R.R. *et al.* 2004. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. *Cancer Detect Prev.* ;28(3):178-86.
- Watson P.H., Safneck J.R., Le .K, Dubik D. and Shiu R.P.1993. Relationship of c-Myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. *J Natl Cancer Inst.* 85:902-907.
- Weber A.L., Romo L. and Hashmi S. 2003. Malignant tumors of the oral cavity and oropharynx: clinical, pathologic, and radiologic evaluation. *Neuroimaging Clin N Am*, 13, 443-64.

- Weinberger P.M., Yu Z., Haffty B.G., Kowalski D., Harigopal M. and Brandsma J. *et al.* 2006. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol* 24(5): 736–747.
- Wilson G.D., Saunders M.I., Dische S., Richman P.I., Daley F.M. and Bentzen S.M. 2001. bcl-2 expression in head and neck cancer: an enigmatic prognostic marker. *Int J Radiat Oncol Biol Phys.* 1;49(2):435-41.
- Withers H.R., Taylor J.M. and Maciejewski B. 1988. The hazard of accelerated tumor clonogen repopulation during radiotherapy. *Acta Oncol*, 27, 131-46.
- Wu M., Ding H.F. and Fisher D.E. 2001. Apoptosis:Molecular Mechanisms. *ENCYCLOPEDIA OF LIFE SCIENCES.* www.els.net.
- Yan J.J., Tzeng C.C. and Jin Y.T. 1996. Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: an immunohistochemical and clinicopathological study. *J Oral Pathol Med* ;25:55–59.
- Yoo J., Jung J.H., Choi H.J., Kang S.J., and Kang C.S. 2004. The Expression of c-myc, bcl-2 and p53 Proteins in Adenocarcinomas of Lung. *Cancer Res Treat.* 36(2): 146–150.
- Yu Y., Dong W., Li X., Yu E., Zhou X. and Li S. 2003. Significance of c-Myc and Bcl-2 Protein Expression in Nasopharyngeal Carcinoma. *Arch Otolaryngol Head Neck Surg.* 129:1322-1326.
- Yuen P.W., Chow V., Choy J., Lam K.Y., Ho W.K. and Wei W.I. 2001. The Clinicopathologic Significance of p53 and p21 Expression in the Surgical Management of Lingual Squamous Cell Carcinoma. *Am J Clin Pathol*;116:240-245.



**HUBUNGAN EKSPRESI P53, Bcl-2, c-Myc dan MMP-9 DENGAN GAMBARAN KLINIKOPATOLOGIS
PADA PENDERITA
KARSINOMA SEL SKUAMOSA KEPALA DAN LEHER DI RSUD dr. ZAINOEL ABIDIN
AZWAR, DR., SP.MK., SP.THT-KL, Prof. dr. Sofia Mubarika, M.Med.Sc., Ph.D.; dr. Agus Surono, SpTHT-KL, Ph.D.
Universitas Gadjah Mada, 2015 | Diunduh dari <http://etd.repository.ugm.ac.id/>**